Genting Malaysia's US$41mil buyout of Empire Resorts flagged as pricey, profit-dilutive
Hong Leong Investment Bank (HLIB) highlighted that the deal values GERL at an enterprise value-to-
earnings before interest, taxes, depreciation, and amortisation multiple of 72.7 times — far above the industry average of around 10 times for US-listed casino operators such as Las Vegas Sands, MGM Resorts, and Wynn Resorts.
"Given the stark premium relative to sector benchmarks, we consider the proposed transaction to be pricey," HLIB said in a note on Monday.
GERL owns Empire Resorts, which operates Resorts World Catskills, Resorts World Hudson Valley, and the mobile betting platform Resorts World Bet. The acquisition also includes the assumption of a US$39.7 million (RM171 million) intercompany loan from Empire Resorts to Kien Huat Realty III Ltd — the Lim family's private investment vehicle.
Subject to regulatory approvals, the acquisition is expected to be complete in the second quarter of FY2025.
Although the deal will give GenM full control of Empire Resorts, HLIB warned it could pressure the group's financials. Total borrowings may rise by RM1.3 billion, lifting the gearing ratio from 1.04 times to 1.15 times and adding up to RM70 million in annual interest costs by FY2026–2027.
Since acquiring a 49 per cent stake in Empire Resorts from Kien Huat Realty in 2019 for US$128 million, GenM has struggled to turn the business around.
While HLIB acknowledged potential synergies and operational efficiencies across the Resorts World brand, it expects losses from GERL to widen, with GenM's share of losses potentially increasing by RM23 million in FY2025 — translating to a possible 3.5 per cent earnings hit over the next three years.
Following its annual update, HLIB raised core earnings forecasts for FY2025 and FY2026 by 5 per cent and 1 per cent, respectively, and introduced an FY2027 core PATMI forecast of RM728.7 million (a 10 per cent year-on-year increase). However, it has not yet factored in the acquisition due to its pending completion.
With GenM's share price falling 26 per cent since its 4Q 2024 results, HLIB has upgraded the stock to Hold (from Sell) but trimmed its target price to RM1.80 (from RM1.99), reflecting the acquisition's risks.
Meanwhile, PublicInvest Research remained bearish, projecting that Empire Resorts will continue to incur losses due to market cannibalisation following the December 2022 launch of Resorts World Hudson Valley.
"Between FY2020 and FY2024, GenM has recognised total associated losses of RM160 million to RM280 million a year, which we attribute the bulk of this to Empire Resorts, the firm said in a note.
PublicInvest downgraded Genma to "Trading Sell" and slashed its target price to RM1.66 (from RM2.53), citing the deal's potential to delay earnings recovery and concerns over corporate governance, calling the related party transaction "unfavourable.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
an hour ago
- Malaysian Reserve
American Trust Investment Services Leads Cre8 Enterprise Ltd. IPO on Nasdaq
ATIS Underscores Commitment to Growth Companies in FinTech and Regulatory Technology Sectors NEW YORK, July 23, 2025 /PRNewswire/ — American Trust Investment Services, Inc. (ATIS) today announced that it served as lead underwriter for Cre8 Enterprise Ltd. (NASDAQ: CRE) in connection with its initial public offering. The offering consisted of 1,450,000 Class A ordinary shares at a public offering price of $4.00 per share, generating gross proceeds of approximately $5.8 million before underwriting discounts and offering expenses. Shares of Cre8 Enterprise Ltd. begin trading today on the Nasdaq Capital Market under the ticker symbol 'CRE.' Cre8 Enterprise Ltd., based in Hong Kong, is a leading provider of integrated financial printing and disclosure services. The company, founded in 2006, serves a diverse range of clients, including Hong Kong–listed companies, IPO applicants, and private enterprises. Its offerings include financial printing, typesetting, translation, logistics, e-submission services, and regulatory technology solutions, all supported by a 24/7 operating model. The net proceeds from the offering will support Cre8's continued investment in its regulatory technology platform, enhancement of printing and logistics capacity, and other general corporate purposes, as outlined in the company's registration statement. 'Helping Cre8 achieve this important milestone reinforces ATIS's role as a trusted partner to companies at the intersection of technology and financial services,' said Ian Lippy, Chief Operating Officer of ATIS. 'We are proud to support their journey to the public markets and look forward to seeing their continued success as a Nasdaq-listed company.' 'At ATIS, we focus on transactions that combine solid fundamentals with technology-led growth,' said James L. Clarren, Chief Compliance Officer and Head of Equity Capital Markets at ATIS. 'Cre8's leadership in financial printing and e-disclosure platforms positions it perfectly at the intersection of regulation and innovation.' This offering builds on ATIS's momentum in lead-managing high-impact transactions. The firm remains focused on serving mid-market growth companies with a hands-on execution model, regulatory insight, and institutional reach. About American Trust Investment Services, Inc. American Trust Investment Services, Inc. (ATIS) is a leading investment bank and financial services firm that provides tailored capital markets solutions for growth-driven companies. Headquartered in Chicago, with offices nationwide, ATIS offers investment banking, brokerage, and advisory services. Known for its hands-on approach, ATIS has guided companies through complex financial transactions with integrity, expertise, and consistent execution. For more information, visit Media & Company Contact:Ian E. LippyAmerican Trust Investment Services, Inc. (ATIS)media@
Malaysian Reserve
2 hours ago
- Malaysian Reserve
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 23, 2025 /CNW/ — USA News Group News Commentary – Cancer diagnoses are climbing fastest among younger women, sparking alarm that looming cuts to U.S. research budgets could stall progress in prevention and treatment. Adding to the strain, federal and state regulators are re‑examining mRNA vaccines, creating a cloud of uncertainty over future cancer‑funding priorities. Yet even amid this policy turbulence, a new wave of oncology innovators is lining up near‑term milestones that could reshape the landscape—led by Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Cue Biopharma, Inc. (NASDAQ: CUE), Verastem, Inc. (NASDAQ: VSTM), Allogene Therapeutics, Inc. (NASDAQ: ALLO), and Perspective Therapeutics, Inc. (NYSE-American: CATX). While regulatory red tape tightens, surging diagnoses of colorectal and other GI cancers in young people demand quicker innovation in oncology. Forecasts suggest worldwide cancer‑drug revenues could blow past US$900 billion by 2034. Within that, next‑gen therapies built on precision techniques are slated to reach US$175.2 billion, advancing at a brisk 7.35% annual clip. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) recently held a well‑attended key opinion leader (KOL) webinar where pancreatic and gastrointestinal cancer specialists dissected pelareorep's clinical history, its biomarker data package, and where the oncolytic virus could slot into evolving chemotherapy and immunotherapy regimens. 'I want to thank our esteemed panel of oncologists for their meaningful contributions to our KOL event,' said Jared Kelly, CEO of Oncolytics. 'Their insights underscore a critical and timely message: pelareorep is a compelling immunotherapy platform that is well situated for combination strategies and a highly differentiated asset for pharma partners looking to expand or establish leadership in GI oncology. We are committed to moving forward aggressively toward registrational development while engaging with partners who share our vision of transforming outcomes in these difficult-to-treat cancers.' The panel revisited survival gains in metastatic pancreatic ductal adenocarcinoma (mPDAC), reviewed translational evidence of 'cold‑to‑hot' tumor conversion, and outlined next steps for a registration-enabling study. Management said feedback from the discussion would inform both upcoming trial designs and partnering talks now underway. The event came on the heels of Oncolytics having rolled out an expanded translational‑data review that tightened the scientific case for pelareorep, an intravenously delivered oncolytic reovirus. Renewed analyses from the GOBLET gastrointestinal cancer study and the AWARE‑1 breast cancer study confirmed that the virus replicates inside tumors, switches on interferon signaling in the immune system, and draws tumor‑infiltrating lymphocytes into the tumor microenvironment. 'This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action,' said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. 'We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME – all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep.' Investigators also recorded higher PD‑L1 expression and tracked newly expanded cytotoxic T‑cell clones in blood samples that matched those inside shrinking lesions—molecular fingerprints that point to stronger responses when pelareorep is combined with standard-of-care treatments and checkpoint inhibitors. 'The collection of data here show that pelareorep works how a cancer immunotherapy should work,' said Jared Kelly, CEO of Oncolytics. 'Pelareorep is a versatile product candidate with strong platform potential to enhance immunological responses in multiple indications, including hard-to-treat cancers. Such compelling findings should be exciting to strategic partners focused on finding a platform immunotherapy in large indications with high unmet medical needs.' Clinical outcomes already hint at real‑world benefit. In more than 100 first‑line mPDAC patients, pelareorep‑based regimens achieved a 21.9% two‑year overall‑survival rate versus a 9.2% historical benchmark. A separate single‑arm study that paired pelareorep with chemotherapy and a checkpoint blocker produced a 62% objective‑response rate—especially notable given that no checkpoint therapy is approved in this cancer today. In hormone‑receptor‑positive, HER2‑negative metastatic breast cancer (HR+/HER2‑ mBC), two randomized trials added more than ten months of median overall survival, while BRACELET‑1 nearly doubled median progression‑free survival to 12.1 months compared with 6.4 months for control patients. To steer these data toward value‑creating deals and late‑stage trials, the company strengthened its leadership earlier this year by appointing industry veteran Jared Kelly as CEO and naming Andrew Aromando Chief Business Officer. The duo previously helped guide Ambrx Biopharma into a US$2 billion sale to Johnson & Johnson, experience the board believes will support capital‑efficient development and strategic partnering for pelareorep. 'Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications,' said Kelly. 'With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy.' As CBO, Aromando is now leading global business development and helping shape the company's corporate, clinical, and regulatory strategies. The leadership tandem is expected to prioritize partnering and expansion opportunities while preserving capital efficiency—a strategy well-suited for pelareorep's growing clinical profile. 'I'm thrilled to join Oncolytics at such a pivotal moment in its evolution,' said Aromando. 'With promising data in difficult-to-treat cancers and a compelling body of clinical evidence in over 1,100 patients, I believe the Company is uniquely positioned to deliver meaningful value to patients and other stakeholders in the near term.' Pelareorep currently holds FDA Fast Track designations in mPDAC (pancreatic cancer) and HR+/HER2‑ mBC (breast cancer), along with Orphan‑Drug status for pancreatic cancer in the United States and Europe. With mechanistic proof, survival data that outperform historical controls, and fresh validation from the recent KOL event, Oncolytics Biotech is aligning its clinical, regulatory, and business strategies to move pelareorep into registration‑enabling trials and position it as a backbone immunotherapy across solid tumors. CONTINUED… Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the market include: Cue Biopharma, Inc. (NASDAQ: CUE) recently reported that adding CUE‑101 to pembrolizumab produced a 50% overall response rate in patients with recurrent/metastatic HPV‑positive head and neck cancer who had a combined positive score (CPS) ≥ 1, including the same 50% response in those with low CPS 1–19. The regimen has now generated two complete responses, an 88% 12‑month overall survival rate, and a median overall survival of 32 months, handily outperforming historical pembrolizumab data. 'The culmination of maturing data further support our conviction that CUE-101, representative of our approach with the CUE-100 series, demonstrates a potential breakthrough therapeutic approach for establishing a new standard of care,' said Dan Passeri, CEO of Cue Biopharma. 'With this maturing data, we are further emboldened in our conviction that our Immuno-STAT® platform represents transformative potential for selectively modulating the patient's immune system.' Verastem, Inc. (NASDAQ: VSTM) recently published Phase 2 RAMP 201 results in the Journal of Clinical Oncology, showing avutometinib + defactinib delivered a 31% confirmed overall response rate in recurrent low‑grade serous ovarian cancer, rising to 44% in KRAS‑mutant tumors. 'The publication of the primary analysis of the RAMP 201 study in recurrent low-grade serous ovarian cancer in the Journal of Clinical Oncology reflects the meaningful clinical advancement demonstrated by the combination of avutometinib plus defactinib for patients with recurrent low-grade serous ovarian cancer,' said John Hayslip, M.D., Chief Medical Officer at Verastem Oncology. 'The findings supported the recent FDA approval of the combination in KRAS-mutated recurrent low-grade serous ovarian cancer and our ongoing global Phase 3 RAMP 301 trial of the combination in recurrent low-grade serous ovarian cancer with and without a KRAS mutation.' Median progression‑free survival reached 12.9 months overall and 31.0 months in the KRAS‑mutant subgroup, with 82% of patients experiencing some tumor shrinkage regardless of mutation status. Back in June, Allogene Therapeutics, Inc. (NASDAQ: ALLO) presented updated Phase 1 TRAVERSE data showing a single dose of ALLO‑316 achieved a 31% confirmed response rate in heavily pre‑treated renal cell carcinoma patients whose tumors expressed CD70 in ≥ 50 % of cells. 'ALLO-316 is showing clear evidence of targeted antitumor activity in patients who had failed most or all approved therapies for advanced or metastatic renal cell carcinoma,' said Zachary Roberts, M.D., Ph.D., EVP, Research and Development and Chief Medical Officer at Allogene. 'Our proprietary Dagger technology allows the use of a standard cyclophosphamide and fludarabine-based lymphodepletion regimen with a single dose of ALLO-316. Strong CAR T-cell kinetics and extensive infiltration of tumor tissue by CAR T cells are combining to generate deep and durable remissions. These are results that were previously considered out of reach for patients with advanced solid tumors.' Four of five responders remain in remission—including one lasting more than 12 months—while safety remained manageable with no graft‑versus‑host disease observed. Investigators say the results highlight allogeneic CAR T's potential in solid tumors and justify continued expansion of the study. Perspective Therapeutics, Inc. (NYSE-American: CATX) recently began recruiting the third dose‑escalation cohort of its Phase 1/2a trial testing [²¹²Pb]VMT‑α‑NET in unresectable or metastatic somatostatin receptor 2 (SSTR2)‑positive neuroendocrine tumors, raising the fixed dose by 20% to 6 mCi. Earlier cohorts showed anti‑tumor activity with mostly low‑grade adverse events, prompting FDA alignment to explore whether the higher dose can further enhance efficacy. 'We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial,' commented Markus Puhlmann, Chief Medical Officer of Perspective. 'We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile.' The company plans additional safety and efficacy readouts, including dosimetry analyses, at scientific meetings in 2H 2025. Source: CONTACT:USA NEWS GROUPinfo@ 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ('MIQ'). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Logo –
New Straits Times
3 hours ago
- New Straits Times
Lim Guan Eng told businessman to open account for bribes, court hears
KUALA LUMPUR: Former Penang chief minister Lim Guan Eng instructed a businessman to open a bank account to funnel bribes linked to the Penang Undersea Tunnel project, the Sessions Court heard today. G. Gnanaraja said the DAP chairman told him this during their first meeting while travelling inside Consortium Zenith Construction Sdn Bhd (CZCSB) director Datuk Zarul Ahmad Mohd Zulkifli's car on Aug 20, 2017. CZCSB was the company awarded the RM6.34 billion Penang undersea tunnel project. The 42-year-old businessman said this while testifying as a key prosecution witness in Lim's corruption trial involving the construction of a major road and undersea tunnel project in Penang worth RM6.3 billion. Lim is also the Bagan Member of Parliament. Gnanaraja said he used his company, Bumi Muhibah Holding Sdn Bhd, as the vehicle to channel bribe payments to Lim. "The company was established on Aug 10, 2016, and registered under the names Aminah Madian and Mohd Rezal Jantan as directors. "Later, in August 2017, I intended to use this company as the vehicle for bribe payments to Lim. "This company has only one bank account, and I was the sole person authorised to withdraw money from it. "All the requests to set up the company and its account were made while I was with Lim in a car on the way to Publika on Aug 20, 2017. "Lim also had personally viewed the company's Form 49 during a visit to my house on Aug 29, the same year. "He wanted to see the document to gain personal confidence in the company's management and the preparation of its documents. "Form 49 contained details of the company's directors, managers, and secretary," he said while testifying before Judge Azura Alwi today. Gnanaraja said he was chosen to act as the middleman between Lim and Zarul because he was not affiliated with any opposition parties at the time. He recounted his first task as the middleman when he received RM2 million in cash from Zarul near Eastin Hotel in Petaling Jaya for the purpose of delivering it to Lim on Aug 18, 2017. He said Zarul had put two dark-coloured bags with hand straps and and placed them directly into the boot of his Bentley. Gnanaraja said he knew the bags contained cash because as Zarul placed the first bag, he said "1M," and repeated the same as he placed the second. By "1M", he understood that Zarul meant RM1 million. He said that on Aug 20, Zarul contacted him and said they needed to pick up Lim at the Wen Worth Hotel near Pudu. However, the trial was cut short after Gnanaraja began coughing severely and said he was feeling unwell. Lim is facing four charges of using his position as the then Penang chief minister to solicit gratification to help Zarul's company secure the undersea tunnel project. He was alleged to have sought 10 per cent of the profit to be made by the company from Zarul. He was also accused of receiving RM3.3 million for himself and causing two plots of land belonging to the state government to be disposed of to two companies linked to the undersea tunnel project. The trial is set to resume on Aug 19.
